本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Denali Therapeutics Inc.

17.65
+0.21001.20%
成交量:12.88万
成交额:225.58万
市值:25.89亿
市盈率:-6.06
高:17.83
开:17.39
低:17.25
收:17.44
52周最高:28.62
52周最低:10.57
股本:1.47亿
流通股本:1.32亿
量比:0.44
换手率:0.10%
股息:- -
股息率:- -
每股收益(TTM):-2.9114
每股收益(LYR):-2.5705
净资产收益率:-44.44%
总资产收益率:-27.29%
市净率:2.79
市盈率(LYR):-6.87

数据加载中...

2025/01/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/07

重要事件披露

Form 8-K - Current report
2025/01/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/12/31

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/18

重要事件披露

Form 8-K - Current report
2024/11/12

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/08

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/07

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/06

重要事件披露

Form 8-K - Current report
2024/10/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/10

重要事件披露

Form 8-K - Current report
2024/09/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities